Concept Life Sciences and OpenBench launch AI-powered collaboration promising faster drug discovery, reduced risks, and cost-efficient biotech research development.
As per the agreement, Concept Life Sciences and OpenBench partner to combine expertise in medicinal chemistry, in-vitro screening, and validation with OpenBench's structure-based artificial intelligence discovery platform. Before synthesizing a few high-potential hits for additional validation, OpenBench's platform can virtually screen trillions of molecules to identify promising drug candidates.
Concept Life Sciences will then receive the identified compounds for quick in vitro testing and optimization using its combined "design-make-test" method. The firms expect that the integrated approach will reduce the time from target identification to validated hit series to about six months.
The partnership's fees for a successful business model are one of its main characteristics. Customers won't be charged until validated hits are supplied; OpenBench will cover the first discovery costs. According to the firms, this structure is meant to help biotech companies functioning in a difficult fundraising market by removing early-stage financial restrictions.
Biotech companies are increasingly looking for quicker and less risky ways to find high-quality chemical starting points for medication development, according to Steven Holshouser, Head of Business Development for North America at Concept Life Sciences. The partnership's goal, he continued, is to give clients an effective route from target selection to validated and developable hits.
According to Lewis Martin, Chief Scientific Officer of OpenBench, the company's goal is to remove uncertainty and upfront costs from early drug discovery. He pointed out that OpenBench provides clients with verified chemical leads prior to major investment, enabling biotech firms to concentrate their efforts on developing initiatives with greater economic and scientific promise.
The partnership takes place in the midst of ongoing financial constraints in the biotechnology industry, where businesses are searching for increasing capital-efficient approaches for research and development. The two businesses hope to assist biotech companies in accelerating pipeline development while reducing early-stage R&D risks by combining AI-based virtual screening with integrated laboratory validation and medicinal chemistry services.
With its headquarters located in the United Kingdom, Concept Life Sciences offers integrated drug research and development services for cell and gene therapies, small molecules, biologics, and peptides. OpenBench specializes in success-based collaboration models for medicinal developers and AI-powered, structure-based drug development.
Thus, Business Fortune is of the view that this partnership could redefine early-stage drug discovery through faster, lower-risk, AI-based innovation.
